# Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

> **NCT06181175** · NA · UNKNOWN · sponsor: **Azienda Ospedaliero Universitaria Maggiore della Carita** · enrollment: 250 (estimated)

## Conditions studied

- Benign Prostatic Hyperplasia
- Urinary Obstruction
- Lower Urinary Tract Symptoms

## Interventions

- **DRUG:** PEAPROSTIL 600 + Tamsulosin 0.4 mg
- **DRUG:** Tamsulosin 0.4 mg
- **DRUG:** PEAPROSTIL 600 mg

## Key facts

- **NCT ID:** NCT06181175
- **Lead sponsor:** Azienda Ospedaliero Universitaria Maggiore della Carita
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-10-01
- **Primary completion:** 2024-10-30
- **Final completion:** 2025-04-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06181175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06181175, "Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06181175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*